Global Healthy Living Foundation and GoodTe. Inc. Rank Japanese vs. English Speaking Respondents In A Small Global Inflammatory Bowel Disease Study
Japanese-Language Patients Are Diagnosed Nearly Twice As Often Within One Year and Trust Physicians Twice As Often As English-Language Respondents
NYACK, N.Y., May 21, 2025--(BUSINESS WIRE)--A small dual-language Japanese and English survey of 203 patients from 13 countries showed 56 percent of Japanese respondents with IBD were diagnosed within a year of symptom onset vs. 33 percent of those answering in English. The study was jointly conducted by an online IBD patient community, G-Community, a part of GoodTe. Inc., Chiyoda-ku, Tokyo, and the Global Healthy Living Foundation (GHLF) using self-selected participants from online communities and social media. It was designed to informally compare Japanese language respondents to those answering in English.
"Despite its small size and informal nature, this survey is noteworthy because of the disparity in some responses that positively highlight the Japanese IBD experience, including a comparatively short time to diagnosis," Aya Fujiwara, Japan Lead at the Global Living Foundation says.
Conversely, the debilitating effects of inflammatory bowel disease at work and in school were equally present in patients from in both surveyed languages. Fifty-Eight percent of Japanese language respondents and 63 percent of English language respondents reported interference with school while 90 percent of those answering in Japanese and 87 percent in English indicated significant work impact.
"This speaks to the uniform global disease burden of IBD, even after diagnosis," Ms. Fujiwara, added.
In addition, although many Japanese-language respondents were diagnosed within one year, about 21 percent still experienced a delay of over five years—similar to the 25 percent of English-language respondents who faced the same delay.
"We can only assume, from some of the free-form responses that the delayed diagnosis came from those without access to specialists, a difficulty recognizing symptoms, or people without a medical home," Ms. Fujiwara said. "We need to refine these rough findings with additional research."
Japanese respondents showed strong trust in their healthcare providers, with 48 percent of Japanese-language respondents expressing trust—more than twice the rate of English-language respondents (21%).
Survey Details
Conducted by: GoodTe. Inc., Chiyoda-ku, Tokyo (Japanese language) and GHLF (English language)
Survey Dates:
Japan: May 8–12, 2025
Rest of World: May 7–11, 2025
Respondents: People diagnosed with IBD
Method: GoodTe. Inc. /GHLF online communities and social media (Instagram, X)
Total survey respondents: 203
Japanese language respondents: 52 (26%)
English language respondents: 151 (74%)
About GHLF
A global nonprofit founded in 1999, representing patients with chronic disease through education, advocacy, research, and patient support.- GHLF Japanese language IBD page: https://linktr.ee/GHLF_IBD - GHLF English language website: https://ghlf.org/ - Japanese language podcasts and information. Japanese language: Living with IBD—Education and Employment: https://ghlf.org/japan
About GoodTe. Inc. and G Community:
GoodTe was founded in 2018 and its IBD patient group, G Community, began July 2019, has over 3,100 members. Members have access to:
GoodTe Recipe, a collection of IBD-friendly recipes, and Gentle Bites, a gut-friendly snack supported by the Meiji Accelerator program.
Japanese- G Community Japanese language IBD site: https://gcarecommunity.com/ - GoodTe Recipe Japanese language cooking site: https://goodtecommunity.com/ - Gentle Bites Shop Japanese language IBD-friendly snacks: https://shop.goodtecommunity.com/
About Inflammatory Bowel Disease:
IBD is a chronic inflammatory condition affecting intestinal mucosa. Symptoms include abdominal pain, diarrhea, and bloody stool. Its cause is unknown and IBD, affecting nearly 300,000 Japanese people, is designated as an intractable disease by Japan's Ministry of Health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521396543/en/
Contacts
GoodTe. Inc.Takuro Miyazaki, Noriyuki SuzukiEmail: info@goodte.jp
GHLFLouis TharpLTHARP@GHLF.ORG 845-323-8408
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market
KUALA LUMPUR, June 6, 2025 /PRNewswire/ -- In a significant move to advance natural, evidence-based health solutions in Japan, Biotropics Malaysia Berhad has signed a Memorandum of Understanding (MOU) with ASK Intercity Co., Ltd. for the sales and distribution of Physta® Tongkat Ali, Biotropics' proprietary standardized extract, in the Japanese market. The MOU signing took place at the Malaysian Pavillion of the World Expo Osaka 2025, during the opening of 'Sustainable Agriculture Week' witnessed by The Honorable Datuk Seri Haji Mohamad bin Sabu, Minister of Agriculture and Food Security. This partnership unites two companies with a shared commitment to the development and marketing of high-quality, clinically supported herbal ingredients. With decades of industry experience, both companies are dedicated to raising the standards of natural product innovation through scientific rigor, transparency and product integrity. Physta® Tongkat Ali, developed through a landmark collaboration between the Malaysian Government and the Massachusetts Institute of Technology (MIT), stands as one of the world's most clinically studied Tongkat Ali (Eurycoma longifolia) extracts. It is backed by over 20 clinical studies and has been shown to support energy, vitality, libido, immunity, stress management and hormonal health. Recently, new research from Biotropics has uncovered Physta®'s efficacy in supporting hormonal balance and reducing stress in pre- and postmenopausal women—a breakthrough expansion from its earlier positioning as a male-centric supplement. This positions Physta® as a versatile ingredient for a broader demographic, supporting both men and women in managing age-related health challenges naturally. "In light of Japan's rapidly ageing population and growing demand for preventive, plant-based health solutions, we believe Physta® brings timely and relevant benefits," said Haliza Ramli, CEO of Biotropics Malaysia. "There is a surge of interest for Tongkat Ali globally and this collaboration reflects a mutual vision: to deliver clinically supported, high-quality herbal ingredients that meet the needs of discerning, health-conscious consumers." Koichi Hosaka, CEO and Managing Director of ASK Intercity, added, "We are excited to work with Biotropics, a globally respected leader in herbal research. Tongkat Ali is already recognized internationally, and we believe Physta® will be very appealing to Japanese consumers seeking natural vitality, stress support, hormonal balance and even looking for Power of Malaysian original forest". The partnership arrives at a pivotal time: Japan has the world's oldest population, with over 29% aged 65 and above. As healthy ageing becomes a national priority, ingredients like Physta®—with proven benefits and gender-inclusive applications—offer real value to brand owners formulating for this dynamic segment. The MOU aims to redefine natural wellness in one of Asia's most mature and discerning health markets and sets foundation for future cooperation between Malaysia and Japan in the field of herbal science, innovation and market development. Biotropics' portfolio—including BioKesum®, SLP+®, Nu-Femme®, and Eurecta®—continues to expand, driven by strong IP, clinical validation and Malaysia's rich botanical heritage. View original content to download multimedia: SOURCE Biotropics Malaysia
Yahoo
11 hours ago
- Yahoo
JETRO and CIC to Showcase Promising Japanese Biotech Startups at "Japan Innovation Night" during BIO International Convention 2025 in Boston
BOSTON, June 06, 2025--(BUSINESS WIRE)--The Japan External Trade Organization (JETRO) and CIC Japan Desk will once again host "Japan Innovation Night: Best in Biotech" - a groundbreaking event showcasing the latest advancements in biotechnology from Japanese startups. This exclusive gathering will take place on Wednesday, June 18th, 2025, from 5:30pm to 8pm in Venture Café at CIC Cambridge. This event provides a unique opportunity for U.S. venture capital firms and pharmaceutical companies, particularly those based in the Greater Boston Area, to explore potential partnerships and synergies with innovative Japanese biotech firms. That same week, JETRO will also be organizing the Japan Pavilion at BIO International Convention 2025 in Boston; therefore, JETRO is pleased to bring several of the exhibiting startups to present their products in a more intimate setting at Japan Innovation Night. The event will feature ten carefully selected startups that will each be given three-minute pitches to present their latest innovations and partnering strategies and goals. A networking session will also be arranged for after the pitch session. In 2024, the Japanese government updated its Bioeconomy Strategy, expressing its intent to step up its support for bioeconomy fields in Japan. This is on top of an already one trillion-yen budget measure enacted by the Japanese government in fiscal year 2022. The Bioeconomy Strategy underscores the Japanese government's commitment to expanding Japan's bioeconomy in the hopes of providing solutions to a myriad of societal and economic issues, from the environment to food to health and economic development. In the Strategy, the Japanese government commits to enhancing the local startup ecosystem, ensuring its support aligns with the domestic biomanufacturing sector's structure and the challenges its players face. By coordinating initiatives across government efforts, the Bioeconomy Strategy aims to establish environments that foster startup creation, growth, and R&D. JETRO will introduce innovative startups from this market at Japan Innovation Night. Full List of Japanese Startups: Pre-Registration Here: About JETRO The Japan External Trade Organization (JETRO) is a Japanese government-affiliated agency that supports Japanese businesses expanding globally and international businesses entering Japan. JETRO helps to facilitate collaboration and business alliances between Japanese and overseas companies via its business platform "J-Bridge." About CIC CIC builds and operates a global network of innovation campuses where startups, scale-ups, corporations and public entities connect, work, and grow. Founded in 1999, CIC manages 1.5 million square feet of innovation-focused workspace, laboratories, and event space across North America, Europe and Asia. Additionally, CIC develops bespoke programming, builds and enables industry clusters, and provides world-class district consulting—all focused on advancing innovation. View source version on Contacts Ryota HiramotoJETRO New YorkRyota_Hiramoto@ 1-212-997-0400 Sign in to access your portfolio
Business Wire
11 hours ago
- Business Wire
JETRO and CIC to Showcase Promising Japanese Biotech Startups at "Japan Innovation Night" during BIO International Convention 2025 in Boston
BOSTON--(BUSINESS WIRE)--The Japan External Trade Organization (JETRO) and CIC Japan Desk will once again host " Japan Innovation Night: Best in Biotech" - a groundbreaking event showcasing the latest advancements in biotechnology from Japanese startups. This exclusive gathering will take place on Wednesday, June 18th, 2025, from 5:30pm to 8pm in Venture Café at CIC Cambridge. This event provides a unique opportunity for U.S. venture capital firms and pharmaceutical companies, particularly those based in the Greater Boston Area, to explore potential partnerships and synergies with innovative Japanese biotech firms. That same week, JETRO will also be organizing the Japan Pavilion at BIO International Convention 2025 in Boston; therefore, JETRO is pleased to bring several of the exhibiting startups to present their products in a more intimate setting at Japan Innovation Night. The event will feature ten carefully selected startups that will each be given three-minute pitches to present their latest innovations and partnering strategies and goals. A networking session will also be arranged for after the pitch session. In 2024, the Japanese government updated its Bioeconomy Strategy, expressing its intent to step up its support for bioeconomy fields in Japan. This is on top of an already one trillion-yen budget measure enacted by the Japanese government in fiscal year 2022. The Bioeconomy Strategy underscores the Japanese government's commitment to expanding Japan's bioeconomy in the hopes of providing solutions to a myriad of societal and economic issues, from the environment to food to health and economic development. In the Strategy, the Japanese government commits to enhancing the local startup ecosystem, ensuring its support aligns with the domestic biomanufacturing sector's structure and the challenges its players face. By coordinating initiatives across government efforts, the Bioeconomy Strategy aims to establish environments that foster startup creation, growth, and R&D. JETRO will introduce innovative startups from this market at Japan Innovation Night. Full List of Japanese Startups: Pre-Registration Here: About JETRO The Japan External Trade Organization (JETRO) is a Japanese government-affiliated agency that supports Japanese businesses expanding globally and international businesses entering Japan. JETRO helps to facilitate collaboration and business alliances between Japanese and overseas companies via its business platform "J-Bridge." About CIC CIC builds and operates a global network of innovation campuses where startups, scale-ups, corporations and public entities connect, work, and grow. Founded in 1999, CIC manages 1.5 million square feet of innovation-focused workspace, laboratories, and event space across North America, Europe and Asia. Additionally, CIC develops bespoke programming, builds and enables industry clusters, and provides world-class district consulting—all focused on advancing innovation.
